alendronate has been researched along with Fibrocartilaginous Dysplasia of Bone in 7 studies
alendronic acid : A 1,1-bis(phosphonic acid) that is methanebis(phosphonic acid) in which the two methylene hydrogens are replaced by hydroxy and 3-aminopropyl groups.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Alendronate treatment led to a reduction in the bone resorption marker NTX-telopeptides, and improvement in aBMD, but no significant effect on serum osteocalcin, pain, or functional parameters." | 6.79 | A randomized, double blind, placebo-controlled trial of alendronate treatment for fibrous dysplasia of bone. ( Bianco, P; Boyce, AM; Brillante, BA; Collins, MT; Kelly, MH; Kushner, H; Riminucci, M; Robey, PG; Wientroub, S, 2014) |
| "Alendronate treatment led to a reduction in the bone resorption marker NTX-telopeptides, and improvement in aBMD, but no significant effect on serum osteocalcin, pain, or functional parameters." | 2.79 | A randomized, double blind, placebo-controlled trial of alendronate treatment for fibrous dysplasia of bone. ( Bianco, P; Boyce, AM; Brillante, BA; Collins, MT; Kelly, MH; Kushner, H; Riminucci, M; Robey, PG; Wientroub, S, 2014) |
| "The degree of pain is highly variable and adults reports more pain than children." | 2.48 | Pathophysiology and medical treatment of pain in fibrous dysplasia of bone. ( Chapurlat, RD; Gensburger, D; Ghilardi, JR; Jimenez-Andrade, JM; Kelly, M; Mantyh, P, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 5 (71.43) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Florez, H | 1 |
| Mandelikova, S | 1 |
| Filella, X | 1 |
| Monegal, A | 1 |
| Guañabens, N | 1 |
| Peris, P | 1 |
| Singh, PT | 1 |
| Burad, D | 1 |
| Hephzibah, J | 1 |
| Paul, TV | 1 |
| Boyce, AM | 1 |
| Kelly, MH | 1 |
| Brillante, BA | 1 |
| Kushner, H | 1 |
| Wientroub, S | 1 |
| Riminucci, M | 1 |
| Bianco, P | 1 |
| Robey, PG | 1 |
| Collins, MT | 1 |
| Lv, M | 1 |
| Li, X | 1 |
| Huang, Y | 1 |
| Wang, N | 1 |
| Zhu, X | 1 |
| Sun, J | 1 |
| Chao, K | 1 |
| Katznelson, L | 1 |
| Chapurlat, RD | 1 |
| Gensburger, D | 1 |
| Jimenez-Andrade, JM | 1 |
| Ghilardi, JR | 1 |
| Kelly, M | 1 |
| Mantyh, P | 1 |
| Lane, JM | 1 |
| Khan, SN | 1 |
| O'Connor, WJ | 1 |
| Nydick, M | 1 |
| Hommen, JP | 1 |
| Schneider, R | 1 |
| Tomin, E | 1 |
| Brand, J | 1 |
| Curtin, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Placebo-Controlled Trial of Alendronate in the Treatment of Polyostotic Fibrous Dysplasia and the McCune-Albright Syndrome[NCT00001728] | Phase 2 | 40 participants (Actual) | Interventional | 1998-08-24 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for alendronate and Fibrocartilaginous Dysplasia of Bone
| Article | Year |
|---|---|
Pathophysiology and medical treatment of pain in fibrous dysplasia of bone.
Topics: Alendronate; Antibodies, Monoclonal, Humanized; Bone and Bones; Bone Neoplasms; Fibrous Dysplasia of | 2012 |
1 trial available for alendronate and Fibrocartilaginous Dysplasia of Bone
| Article | Year |
|---|---|
A randomized, double blind, placebo-controlled trial of alendronate treatment for fibrous dysplasia of bone.
Topics: Adolescent; Adult; Alendronate; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Rem | 2014 |
5 other studies available for alendronate and Fibrocartilaginous Dysplasia of Bone
| Article | Year |
|---|---|
Clinical significance of increased serum levels of FGF-23 in fibrous dysplasia.
Topics: Adult; Aged; Alendronate; Biomarkers; Bone Density Conservation Agents; Female; Fibroblast Growth Fa | 2018 |
Uncommon cause for chest pain.
Topics: Adult; Alendronate; Bone Density Conservation Agents; Chest Pain; Drug Administration Schedule; Fibr | 2018 |
Inhibition of fibrous dysplasia via blocking Gsα with suramin sodium loaded with an alendronate-conjugated polymeric drug delivery system.
Topics: Alendronate; Animals; Bone Marrow Cells; Cell Culture Techniques; Cell Line; Drug Carriers; Durapati | 2016 |
Use of high-dose oral bisphosphonate therapy for symptomatic fibrous dysplasia of the skull.
Topics: Administration, Oral; Adult; Alendronate; Bone Density Conservation Agents; Dose-Response Relationsh | 2008 |
Bisphosphonate therapy in fibrous dysplasia.
Topics: Administration, Oral; Adult; Aged; Alendronate; Biomarkers; Bone and Bones; Collagen; Collagen Type | 2001 |